Australian-Singaporean medtech leader Osteopore (ASX:OSX) signed a collaboration agreement with Tan Tock Seng Hospital.
The partnership focuses on the co-development of a pioneering, 3D-printed biomimetic implant designed specifically to treat avascular necrosis of the hip joint—a debilitating condition where bone tissue dies due to a lack of blood supply.
The agreement serves as a formalised follow-up to two substantial research milestones: the National Health Innovation Centre Singapore Innovation-to-Industry grant, announced in February, and the NHG Health's Centre for Medical Technologies & Innovations MedTech Grant, awarded in September 2025.
By leveraging Osteopore's expertise in bioresorbable materials and TTSH’s clinical excellence as a major anchor hospital within Singapore’s National Healthcare Group, the project aims to move from lab-based innovation to real-world surgical application.
For patients suffering from AVN, the development represents a shift toward more natural, regenerative healing processes rather than traditional permanent metallic replacements.
The collaboration underscores a firm commitment from both organisations to tackle complex orthopaedic challenges through advanced technology and local manufacturing capabilities, potentially setting a new standard for hip joint preservation treatments globally.
At the time of reporting, Osteopore's share price was $0.0080.